Med-Tech Innovation editor Ian Bolland speaks to Lionel Maritan, associate director – research and development Becton Dickinson (BD), about the company’s Intevia 2.25ml autoinjector which is set to launch at the end of 2021 or the start of 2022.
Injection
Maritan begins by explaining that the new product is still in its development phase and will be dedicated to injecting drugs at a higher volume compared to previous devices the company has launched.
The 2.25ml disposable autoinjector is a combination product designed to deliver a range of viscous drugs for patients suffering from chronic diseases. Since chronic disease patients undergoing biologics treatments often need to inject frequently, the device has been designed for home use and to be easy to hold. Used with pre-fillable syringes, Intevia works through a two-step process, with the patient first placing the autoinjector on their skin before pressing a button once to deliver the prescribed dose.